A phase 1 trial of APX-343A, NOX inhibitor targeting CAF-mediated immunosuppression, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
Authors: Hyesung Shin, Sung Hwan Moon, Soo Jin Lee, Yoenhee Ahn
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.tps2697
Source:
Full article
Abstract
TPS2697